These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 18381960

  • 1. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
    Oliver PG, LoBuglio AF, Zinn KR, Kim H, Nan L, Zhou T, Wang W, Buchsbaum DJ.
    Clin Cancer Res; 2008 Apr 01; 14(7):2180-9. PubMed ID: 18381960
    [Abstract] [Full Text] [Related]

  • 2. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
    Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S, Carpenter M, LoBuglio AF.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 1):3731-41. PubMed ID: 14506165
    [Abstract] [Full Text] [Related]

  • 3. The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.
    Zhu H, Zhao F, Yu S, He J, Deng L, Yi C, Huang Y.
    Int J Mol Med; 2012 Nov 01; 30(5):1087-94. PubMed ID: 22922573
    [Abstract] [Full Text] [Related]

  • 4. Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.
    DeRosier LC, Buchsbaum DJ, Oliver PG, Huang ZQ, Sellers JC, Grizzle WE, Wang W, Zhou T, Zinn KR, Long JW, Vickers SM.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 2):5535s-5543s. PubMed ID: 17875786
    [Abstract] [Full Text] [Related]

  • 5. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
    Straughn JM, Oliver PG, Zhou T, Wang W, Alvarez RD, Grizzle WE, Buchsbaum DJ.
    Gynecol Oncol; 2006 Apr 15; 101(1):46-54. PubMed ID: 16271751
    [Abstract] [Full Text] [Related]

  • 6. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
    Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA.
    Cancer Res; 2002 Oct 15; 62(20):5800-6. PubMed ID: 12384541
    [Abstract] [Full Text] [Related]

  • 7. Effect of anti-DR5 and chemotherapy on basal-like breast cancer.
    Oliver PG, LoBuglio AF, Zhou T, Forero A, Kim H, Zinn KR, Zhai G, Li Y, Lee CH, Buchsbaum DJ.
    Breast Cancer Res Treat; 2012 Jun 15; 133(2):417-26. PubMed ID: 21901385
    [Abstract] [Full Text] [Related]

  • 8. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
    Ueno T, Endo S, Saito R, Hirose M, Hirai S, Suzuki H, Yamato K, Hyodo I.
    Oncol Res; 2013 Jun 15; 21(3):155-64. PubMed ID: 24512730
    [Abstract] [Full Text] [Related]

  • 9. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.
    Kaliberov S, Stackhouse MA, Kaliberova L, Zhou T, Buchsbaum DJ.
    Gene Ther; 2004 Apr 15; 11(8):658-67. PubMed ID: 14973547
    [Abstract] [Full Text] [Related]

  • 10. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants.
    Jansen WJ, Zwart B, Hulscher ST, Giaccone G, Pinedo HM, Boven E.
    Int J Cancer; 1997 Jan 27; 70(3):335-40. PubMed ID: 9033637
    [Abstract] [Full Text] [Related]

  • 11. Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts.
    Sugamura K, Gibbs JF, Belicha-Villanueva A, Andrews C, Repasky EA, Hylander BL.
    Oncology; 2008 Jan 27; 74(3-4):188-97. PubMed ID: 18714167
    [Abstract] [Full Text] [Related]

  • 12. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S, Almasan A.
    Cancer Res; 2003 Aug 01; 63(15):4713-23. PubMed ID: 12907654
    [Abstract] [Full Text] [Related]

  • 13. Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.
    Bevis KS, McNally LR, Sellers JC, Della Manna D, Londoño Joshi A, Amm H, Straughn JM, Buchsbaum DJ.
    Gynecol Oncol; 2011 Apr 01; 121(1):193-9. PubMed ID: 21211830
    [Abstract] [Full Text] [Related]

  • 14. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS, Jung KA, Kim SM, Hong YS, Ryu MH, Jang SJ, Moon DH, Cho DH, Kim JC, Lee JS, Kim TW.
    Cancer Chemother Pharmacol; 2011 Aug 01; 68(2):389-98. PubMed ID: 21046105
    [Abstract] [Full Text] [Related]

  • 15. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
    DeRosier LC, Huang ZQ, Sellers JC, Buchsbaum DJ, Vickers SM.
    J Gastrointest Surg; 2006 Nov 01; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
    [Abstract] [Full Text] [Related]

  • 16. Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.
    Kim H, Zhai G, Samuel SL, Rigell CJ, Umphrey HR, Rana S, Stockard CR, Fineberg NS, Zinn KR.
    Mol Cancer Ther; 2012 Feb 01; 11(2):405-15. PubMed ID: 22203731
    [Abstract] [Full Text] [Related]

  • 17. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
    Fukushima M, Sakamoto K, Ohshimo H, Nakagawa F, Taguchi T.
    Oncol Rep; 2010 Oct 01; 24(4):835-42. PubMed ID: 20811661
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.
    Motwani M, Jung C, Sirotnak FM, She Y, Shah MA, Gonen M, Schwartz GK.
    Clin Cancer Res; 2001 Dec 01; 7(12):4209-19. PubMed ID: 11751522
    [Abstract] [Full Text] [Related]

  • 20. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
    LaBonte MJ, Manegold PC, Wilson PM, Fazzone W, Louie SG, Lenz HJ, Ladner RD.
    Int J Cancer; 2009 Dec 15; 125(12):2957-69. PubMed ID: 19536776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.